PPADS, a purinergic antagonist reduces Fos expression at spinal cord level in a mouse model of mononeuropathy

E. Borsani, R. Albertini, M. Colleoni, P. Sacerdote, A. E. Trovato, C. Lonati, M. Labanca, A. E. Panerai, R. Rezzani, L. F. Rodella

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Recent evidence suggest that ATP plays a role as an endogenous pain mediator generating and/or modulating pain signaling from the periphery to the spinal cord. In this study we evaluated the effects of intraperitoneal administration of P2 receptor antagonist, pyridoxalphosphate-6-azophenyl-2′,4′-disulphonic acid (PPADS), evaluating pain related behaviours and monitoring the expression of Fos, a marker of activated neurons, in an experimental mouse model of neuropathic pain (sciatic nerve tying). The PPADS administration decreased both tactile allodynia and thermal hyperalgesia in a time and dose dependent manner. The dose of 25 mg/kg PPADS completely reversed nociceptive hypersensitivity. Moreover, non-noxious stimulation induced an increase of Fos positive neurons in the spinal cord of animals with tying of sciatic nerve. PPADS administration partially reversed this increase. These results suggest that PPADS reduces neuronal activation at spinal cord level and that P2 receptors are involved in the retrograde signalling progress exciting sensory spinal neurons.

Original languageEnglish
Pages (from-to)74-81
Number of pages8
JournalBrain Research
Volume1199
DOIs
Publication statusPublished - Mar 14 2008

Fingerprint

Purinergic Antagonists
Mononeuropathies
Spinal Cord
Hyperalgesia
Acids
Sciatic Nerve
Pain
Neurons
Neuralgia
Sensory Receptor Cells
Hypersensitivity
Theoretical Models
Adenosine Triphosphate

Keywords

  • Fos
  • Neuropathic pain
  • PPADS
  • Purinergic receptor
  • Spinal cord

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Developmental Biology
  • Molecular Biology

Cite this

Borsani, E., Albertini, R., Colleoni, M., Sacerdote, P., Trovato, A. E., Lonati, C., ... Rodella, L. F. (2008). PPADS, a purinergic antagonist reduces Fos expression at spinal cord level in a mouse model of mononeuropathy. Brain Research, 1199, 74-81. https://doi.org/10.1016/j.brainres.2007.12.066

PPADS, a purinergic antagonist reduces Fos expression at spinal cord level in a mouse model of mononeuropathy. / Borsani, E.; Albertini, R.; Colleoni, M.; Sacerdote, P.; Trovato, A. E.; Lonati, C.; Labanca, M.; Panerai, A. E.; Rezzani, R.; Rodella, L. F.

In: Brain Research, Vol. 1199, 14.03.2008, p. 74-81.

Research output: Contribution to journalArticle

Borsani, E, Albertini, R, Colleoni, M, Sacerdote, P, Trovato, AE, Lonati, C, Labanca, M, Panerai, AE, Rezzani, R & Rodella, LF 2008, 'PPADS, a purinergic antagonist reduces Fos expression at spinal cord level in a mouse model of mononeuropathy', Brain Research, vol. 1199, pp. 74-81. https://doi.org/10.1016/j.brainres.2007.12.066
Borsani, E. ; Albertini, R. ; Colleoni, M. ; Sacerdote, P. ; Trovato, A. E. ; Lonati, C. ; Labanca, M. ; Panerai, A. E. ; Rezzani, R. ; Rodella, L. F. / PPADS, a purinergic antagonist reduces Fos expression at spinal cord level in a mouse model of mononeuropathy. In: Brain Research. 2008 ; Vol. 1199. pp. 74-81.
@article{91185083c30943cd85f70ad01a9e8b4d,
title = "PPADS, a purinergic antagonist reduces Fos expression at spinal cord level in a mouse model of mononeuropathy",
abstract = "Recent evidence suggest that ATP plays a role as an endogenous pain mediator generating and/or modulating pain signaling from the periphery to the spinal cord. In this study we evaluated the effects of intraperitoneal administration of P2 receptor antagonist, pyridoxalphosphate-6-azophenyl-2′,4′-disulphonic acid (PPADS), evaluating pain related behaviours and monitoring the expression of Fos, a marker of activated neurons, in an experimental mouse model of neuropathic pain (sciatic nerve tying). The PPADS administration decreased both tactile allodynia and thermal hyperalgesia in a time and dose dependent manner. The dose of 25 mg/kg PPADS completely reversed nociceptive hypersensitivity. Moreover, non-noxious stimulation induced an increase of Fos positive neurons in the spinal cord of animals with tying of sciatic nerve. PPADS administration partially reversed this increase. These results suggest that PPADS reduces neuronal activation at spinal cord level and that P2 receptors are involved in the retrograde signalling progress exciting sensory spinal neurons.",
keywords = "Fos, Neuropathic pain, PPADS, Purinergic receptor, Spinal cord",
author = "E. Borsani and R. Albertini and M. Colleoni and P. Sacerdote and Trovato, {A. E.} and C. Lonati and M. Labanca and Panerai, {A. E.} and R. Rezzani and Rodella, {L. F.}",
year = "2008",
month = "3",
day = "14",
doi = "10.1016/j.brainres.2007.12.066",
language = "English",
volume = "1199",
pages = "74--81",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",

}

TY - JOUR

T1 - PPADS, a purinergic antagonist reduces Fos expression at spinal cord level in a mouse model of mononeuropathy

AU - Borsani, E.

AU - Albertini, R.

AU - Colleoni, M.

AU - Sacerdote, P.

AU - Trovato, A. E.

AU - Lonati, C.

AU - Labanca, M.

AU - Panerai, A. E.

AU - Rezzani, R.

AU - Rodella, L. F.

PY - 2008/3/14

Y1 - 2008/3/14

N2 - Recent evidence suggest that ATP plays a role as an endogenous pain mediator generating and/or modulating pain signaling from the periphery to the spinal cord. In this study we evaluated the effects of intraperitoneal administration of P2 receptor antagonist, pyridoxalphosphate-6-azophenyl-2′,4′-disulphonic acid (PPADS), evaluating pain related behaviours and monitoring the expression of Fos, a marker of activated neurons, in an experimental mouse model of neuropathic pain (sciatic nerve tying). The PPADS administration decreased both tactile allodynia and thermal hyperalgesia in a time and dose dependent manner. The dose of 25 mg/kg PPADS completely reversed nociceptive hypersensitivity. Moreover, non-noxious stimulation induced an increase of Fos positive neurons in the spinal cord of animals with tying of sciatic nerve. PPADS administration partially reversed this increase. These results suggest that PPADS reduces neuronal activation at spinal cord level and that P2 receptors are involved in the retrograde signalling progress exciting sensory spinal neurons.

AB - Recent evidence suggest that ATP plays a role as an endogenous pain mediator generating and/or modulating pain signaling from the periphery to the spinal cord. In this study we evaluated the effects of intraperitoneal administration of P2 receptor antagonist, pyridoxalphosphate-6-azophenyl-2′,4′-disulphonic acid (PPADS), evaluating pain related behaviours and monitoring the expression of Fos, a marker of activated neurons, in an experimental mouse model of neuropathic pain (sciatic nerve tying). The PPADS administration decreased both tactile allodynia and thermal hyperalgesia in a time and dose dependent manner. The dose of 25 mg/kg PPADS completely reversed nociceptive hypersensitivity. Moreover, non-noxious stimulation induced an increase of Fos positive neurons in the spinal cord of animals with tying of sciatic nerve. PPADS administration partially reversed this increase. These results suggest that PPADS reduces neuronal activation at spinal cord level and that P2 receptors are involved in the retrograde signalling progress exciting sensory spinal neurons.

KW - Fos

KW - Neuropathic pain

KW - PPADS

KW - Purinergic receptor

KW - Spinal cord

UR - http://www.scopus.com/inward/record.url?scp=40049099906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40049099906&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2007.12.066

DO - 10.1016/j.brainres.2007.12.066

M3 - Article

C2 - 18302958

AN - SCOPUS:40049099906

VL - 1199

SP - 74

EP - 81

JO - Brain Research

JF - Brain Research

SN - 0006-8993

ER -